Johnson Johnson JNJ Secures FDA Priority Review for IMAAVY Targeting FirstofItsKind Indication for Warm Autoimmune Hemolytic Anemia The recurring revenue story behind Exodus Movement EXOD Q4 2025 Profit Disappoints PAVS Paranovus shares rise 45 percent despite steep Q2 2022 earnings miss against analyst expectations How JB Hunt JBHT differentiates itself from competitors Smart Money Exits 20260508 Calamos Conv CHI Stock Key Catalysts Ahead The working capital efficiency at Scilex SCLXW SCLXW Q3 Earnings Scilex Warrant Reports No Operating Results The strategic moves Granite GRNT is making now 175 20260508 SGP SpyGlass Pharma reports solid latestage trial progress lays out aggressive commercial expansion plans for 2025